CL2011000244A1 - Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros. - Google Patents

Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros.

Info

Publication number
CL2011000244A1
CL2011000244A1 CL2011000244A CL2011000244A CL2011000244A1 CL 2011000244 A1 CL2011000244 A1 CL 2011000244A1 CL 2011000244 A CL2011000244 A CL 2011000244A CL 2011000244 A CL2011000244 A CL 2011000244A CL 2011000244 A1 CL2011000244 A1 CL 2011000244A1
Authority
CL
Chile
Prior art keywords
particles
treatment
pharmaceutical formulation
myocardial infarction
arterial
Prior art date
Application number
CL2011000244A
Other languages
English (en)
Spanish (es)
Inventor
Ginard Bernardo Nadal
Original Assignee
Coretherapix Slu Es/Es
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39846672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000244(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coretherapix Slu Es/Es filed Critical Coretherapix Slu Es/Es
Publication of CL2011000244A1 publication Critical patent/CL2011000244A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2011000244A 2008-08-05 2011-02-04 Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros. CL2011000244A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0814302.6A GB0814302D0 (en) 2008-08-05 2008-08-05 Compounds and methods

Publications (1)

Publication Number Publication Date
CL2011000244A1 true CL2011000244A1 (es) 2011-07-15

Family

ID=39846672

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000244A CL2011000244A1 (es) 2008-08-05 2011-02-04 Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros.

Country Status (13)

Country Link
US (3) US20120195939A1 (OSRAM)
EP (1) EP2323626B1 (OSRAM)
JP (1) JP5623400B2 (OSRAM)
KR (1) KR101639827B1 (OSRAM)
CN (1) CN102170868A (OSRAM)
AU (1) AU2009279086B2 (OSRAM)
BR (1) BRPI0917571B1 (OSRAM)
CA (1) CA2732785C (OSRAM)
CL (1) CL2011000244A1 (OSRAM)
ES (1) ES2677005T3 (OSRAM)
GB (1) GB0814302D0 (OSRAM)
MX (1) MX2011001261A (OSRAM)
WO (1) WO2010015665A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
WO2014022685A1 (en) * 2012-08-03 2014-02-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Recruitment of mesenchymal cells using controlled release systems
WO2014028493A2 (en) 2012-08-13 2014-02-20 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
EP2914273B1 (en) * 2012-10-26 2018-07-04 Cedars-Sinai Medical Center Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration
AU2014210181A1 (en) * 2013-01-24 2015-09-10 Bernardo Nadal-Ginard Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof
PL2759595T3 (pl) * 2013-01-24 2017-09-29 Pierre Fabre Médicament S.A.S. Kompozycja zawierająca kapsułkowany antagomir
JP6878274B2 (ja) 2014-10-03 2021-05-26 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム
CN104650333B (zh) * 2015-02-05 2016-08-24 浙江大学 聚乳酸/氢化聚丁二烯热塑性超分子弹性体及其制备方法
EP3469996B1 (en) * 2015-03-02 2025-08-27 Accurate Medical Therapeutics Ltd. Catheters with side openings for modifying and delivering suspensions to a subject
JP6743041B2 (ja) 2015-03-30 2020-08-19 タリス バイオメディカル エルエルシー 上部尿路への薬剤の局所的な送達装置及び方法
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
AU2017260879B2 (en) 2016-05-04 2021-11-04 Argon Medical Devices, Inc. Embolization microcatheter head having slitted pattern
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
WO2017220611A1 (en) 2016-06-20 2017-12-28 Virbac Oral pharmaceutical composition comprising a pharmaceutically active agent, at least one cationic bioadhesive polymer and at least two anionic polymers
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018195210A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
IL274383B2 (en) 2017-11-02 2024-03-01 Accurate Medical Therapeutics Ltd Embolization catheter with integral filter
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE
US12414999B2 (en) * 2018-01-12 2025-09-16 President And Fellows Of Harvard College Compositions and methods relating to macrophages and/or monocytes with adhered particles
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
IL287953B1 (en) 2019-05-23 2025-09-01 Accurate Medical Therapeutics Ltd Embolization catheter for reflux-free microsphere administration
US20240082167A1 (en) * 2021-01-22 2024-03-14 University Of Connecticut Synthetic artificial stem cells (sasc)
AU2024214275A1 (en) * 2023-02-02 2025-08-21 Silver Creek Pharmaceuticals, Inc. Methods of treatment using igf-1 chimeric proteins

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
JP4350165B2 (ja) 1994-12-16 2009-10-21 クアドラント、 ドラッグ、 デリバリー、 リミテッド 架橋した微細粒子、及びそれら粒子の治療薬用ビヒクルとしての使用
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
CA2161863A1 (en) 1995-10-31 1997-05-01 Michael Vivian Sefton Angiogenic material and uses thereof
US6511477B2 (en) 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
JP2001524096A (ja) * 1997-04-24 2001-11-27 ニコムド イメージング エイエス コントラスト剤を含む不溶性微粒子または小胞を使用する塞栓治療
DE69714035T2 (de) 1997-08-14 2003-03-06 Sulzer Innotec Ag, Winterthur Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
EP1028746B1 (en) * 1997-11-07 2003-02-26 Chiron Corporation Method for producing igf-i sustained-release formulations
AU6411199A (en) 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
ES2257881T3 (es) 1998-11-18 2006-08-01 Univ Florida Procedimiento para preparar particulas de farmaco revestidas y formulaciones farmaceuticas de las mismas.
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
JPWO2003059375A1 (ja) * 2002-01-17 2005-05-19 株式会社カルディオ 組織再生複合療法
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20040131681A1 (en) * 2002-09-05 2004-07-08 Ambrose Catherine G. Antibiotic microspheres for treatment of infections and osteomyelitis
WO2004084819A2 (en) * 2003-03-19 2004-10-07 University Of Kentucky Research Foundation Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
EP1660039B1 (en) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
US20070116768A1 (en) 2003-12-09 2007-05-24 Michael Chorny Sustained release preparations composed of biocompatible complex microparticles
WO2005094888A1 (ja) * 2004-03-31 2005-10-13 Two Cells Co. Ltd. 損傷組織の治療剤と治療方法
US7854944B2 (en) 2004-12-17 2010-12-21 Advanced Cardiovascular Systems, Inc. Tissue regeneration
ES2273572B1 (es) * 2005-05-04 2008-04-01 Universidad De Sevilla Procedimiento de preparacion de particulas de tamaño micro y nanometrico con productos labiles y particulas obtenidas.
WO2007028053A2 (en) 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
KR100718329B1 (ko) 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
US8506965B2 (en) * 2005-11-11 2013-08-13 Vascular Biosciences R-RAS activity in vascular regulation
JP2009517343A (ja) * 2005-11-14 2009-04-30 エンタープライズ パートナーズ ベンチャー キャピタル 組織損傷のための幹細胞因子療法
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
DK2087890T3 (da) 2006-10-19 2014-05-19 Ono Pharmaceutical Co Præparat med vedvarende frigørelse til vævsregenereringsterapi
WO2008108736A1 (en) 2007-03-06 2008-09-12 Agency For Science, Technology And Research Particles for delivery of bioactive factors
EP2244697A1 (en) 2008-01-29 2010-11-03 Shire Human Genetic Therapies, Inc. Therapeutic compositions
WO2009100128A1 (en) 2008-02-04 2009-08-13 Massachusetts Institute Of Technology Particulate delivery vehicles for embryoid bodies
US20090297621A1 (en) * 2008-06-03 2009-12-03 Abbott Cardiovascular Systems Inc. Microparticles For The Treatment Of Disease
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods

Also Published As

Publication number Publication date
AU2009279086B2 (en) 2014-05-22
ES2677005T3 (es) 2018-07-27
WO2010015665A3 (en) 2010-10-07
WO2010015665A2 (en) 2010-02-11
EP2323626A2 (en) 2011-05-25
KR20110051212A (ko) 2011-05-17
BRPI0917571A2 (pt) 2020-08-11
JP5623400B2 (ja) 2014-11-12
KR101639827B1 (ko) 2016-07-14
CA2732785A1 (en) 2010-02-11
US20120195939A1 (en) 2012-08-02
AU2009279086A1 (en) 2010-02-11
CA2732785C (en) 2016-11-22
BRPI0917571B1 (pt) 2022-01-04
EP2323626B1 (en) 2018-04-11
US20130315997A1 (en) 2013-11-28
US8846099B2 (en) 2014-09-30
US20130189321A1 (en) 2013-07-25
GB0814302D0 (en) 2008-10-01
JP2011529946A (ja) 2011-12-15
CN102170868A (zh) 2011-08-31
MX2011001261A (es) 2011-08-08

Similar Documents

Publication Publication Date Title
CL2011000244A1 (es) Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros.
Heuschkel et al. Microemulsions—modern colloidal carrier for dermal and transdermal drug delivery
Dembitsky Bioactive peroxides as potential therapeutic agents
MX2019009271A (es) Portador de sustancia fisiologicamente activa.
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
CO2018011051A2 (es) Formas de dosificación de liberación modificada disuasivas de abuso
ES2721898T3 (es) Formulaciones estables para liofilizar partículas terapéuticas
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
PE20080210A1 (es) Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrilo (tmc278)
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
CO2020000328A2 (es) Formulaciones a largo plazo
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
MX2015012783A (es) Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13).
AR074062A1 (es) Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
CO2023001340A2 (es) Formulaciones a largo plazo
BR112014009242A2 (pt) nanossuspensão farmacêutica
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
CO2022003583A2 (es) Compuestos de curcumina y aminoácidos básicos
CL2009000330A1 (es) Composicion farmaceutica que comprende microcapsulas de sabor enmascarado con un nucleo de ranitidina y al menos dos recubrimientos sobre el; tabla de rapida desintegracion oral; metodo para preparar la composicion farmaceutica; metodo para preparar la tableta, util para tratar o prevenir trastornos gastrointestinales.
MX363389B (es) Composicion farmaceutica que comprende ivabradina amorfa.